

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 745 131 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
02.01.2003 Bulletin 2003/01

(51) Int Cl.7: **C12N 15/67, C12N 15/85,
A61K 48/00**

(21) Application number: **95908333.8**

(86) International application number:
PCT/GB95/00322

(22) Date of filing: **15.02.1995**

(87) International publication number:
WO 95/021927 (17.08.1995 Gazette 1995/35)

(54) **TARGETING GENE THERAPY**

GEZIELTE GENTHERAPIE

THERAPIE GENIQUE DE CIBLAGE

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB IE IT LI NL SE

(30) Priority: **15.02.1994 GB 9402857**

(43) Date of publication of application:
04.12.1996 Bulletin 1996/49

(60) Divisional application:
01200031.1 / 1 136 561

(73) Proprietor: **Oxford Biomedica (UK) Limited**
Oxford OX4 4GA (GB)

(72) Inventors:

- **RATCLIFFE, Peter John 108 Mill Street**
Oxon OX5 2EF (GB)
- **FIRTH, John David 86 High Street**
Oxford OX3 1XP (GB)
- **HARRIS, Adrian Llewelyn**
Oxford OX2 6RJ (GB)
- **PUGH, Christopher William**
Headington Oxford OX3 8HG (GB)
- **STRATFORD, Ian James**
Bretton, Eyam, Derbyshire S30 1QD (GB)

(74) Representative: **Maschio, Antonio et al**
D Young & Co,
21 New Fetter Lane
London EC4A 1DA (GB)

(56) References cited:

- **BLOOD**, vol. 77, no. 2, 1991 pages 278-285, S. **IMAGAWA ET AL.** 'Regulatory elements of the erythropoietin gene'
- **PROC. NATL. ACAD. SCI. USA**, vol. 90, 1993 pages 2423-2427, P. **MAXWELL ET AL.** 'Inducible operation of the erythropoietin enhancer in multiple cell lines' cited in the application
- **MOL. CELL. BIOL.**, vol. 7, no. 10, 1987 pages 3459-3465, B. **LIM ET AL.** 'Retrovirus-mediated gene transfer of human adenosine deaminase'
- **CANCER AND METASTASIS REVIEWS**, vol. 12, no. 2, 1993 pages 73-82, P. **WORKMAN ET AL.** 'The experimental development of bioreductive drugs and their role in cancer therapy' cited in the application
- **NUC. ACIDS RES.**, vol. 19, no. 20, 1991 pages 5755-5761, M. **MCBURNEY ET AL.** 'The mouse PGK-1 gene promoter contains an upstream activator sequence' cited in the application
- **PROC. NATL. ACAD. SCI. USA**, vol. 90, 1993 pages 3928-3932, A. **MADAN ET AL.** 'A 24 base pair sequence 3' to the human erythropoietin gene contains a hypoxia responsive transcriptional enhancer'
- **TRENDS IN BIOTECHNOLOGY**, vol. 11, no. 5, 1993 pages 197-201, K. **SIKORA** 'gene therapy for cancer'
- **PROC. NATL. ACAD. SCI. USA**, vol. 91, 1994 pages 6496-6500, J. **FIRTH ET AL.** 'Oxygen regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 745 131 B1

Description

[0001] This invention is concerned with hypoxically-inducible expression control sequences, nucleic acid constructs comprising such sequences, and their use for selective targeting of anti-cancer therapy and other kinds of therapy where target cells are affected by hypoxia.

[0002] Vile and Hart (1993) describe a method in which certain gene promoters, which are preferentially active in melanocytic cells, were used to direct gene expression of a reporter gene specifically to melanoma cells in vitro, and in vivo in mice. Constructs consisting of the promoters and the beta-galactosidase gene were directly injected into mice and the reporter gene was expressed in melanoma cells and in some normal melanocytes but not in surrounding normal tissue. However, tissue-specific promoters will necessarily be limited in the tumours that they can target and will also be liable to target normal cells of the tissue concerned (as was noted in Vile and Hart above).

[0003] Cancers tend to outgrow the blood supply and often have areas of hypoxia and necrosis which distinguish them from normal tissue. This feature also makes tumours resistant to radiation due to low oxygen levels and x-ray treatment becomes less effective. Certain genes such as the gene for erythropoietin, are known to be regulated by hypoxia. Erythropoietin is a hormone which regulates erythropoiesis and hence blood oxygen content. Cis-activating DNA sequences that function as tissue-specific hypoxia-inducible enhancers of human erythropoietin expression have been identified (Semenza et al, 1991). A DNA enhancer sequence located 3' to the mouse erythropoietin gene has been shown to confer oxygen-regulated expression on a variety of heterologous promoters (Pugh et al, 1991). It has further been demonstrated that the oxygen-sensing system which controls erythropoietin expression is widespread in mammalian cells (Maxwell et al, 1993).

[0004] A second example of a hypoxia-associated regulator is a regulator which lies 5' to the mouse phosphoglycerate kinase gene promoter. The sequence of the regulator has been published (McBurney et al, 1991) but its hypoxia inducible properties have not previously been considered or defined in the literature. It has now been recognised by the inventors that the native sequence of the regulator has hypoxically-inducible features. The nucleotides responsible have been defined and the inventors have shown that repeating the sequence leads to increased induction of the gene whose expression is controlled. Further, the inventors have shown that using the interleukin-2 gene under tissue-specific promoters is an effective strategy for specific targeting of tumours.

[0005] There are anti-cancer drugs that become activated under hypoxia (Workman and Stratford, 1993), but the use of a drug activation system where the enzyme activating the drugs is greatly increased under hypoxia will provide a far superior therapeutic effect.

[0006] The invention provides a nucleic acid construct comprising at least one gene encoding a cytokine or a prodrug activation system, operatively linked to a hypoxically inducible expression control sequence.

[0007] When the construct is present in a suitable host cell, expression of the gene will thus be regulated according to the level of oxygenation. Preferably the expression control sequence is a promoter or enhancer. In a host cell under hypoxic conditions, expression of the gene will be initiated or upregulated, while under conditions of normoxia (normal oxygen level) the gene will be expressed at a lower level or not expressed at all. The expression level may vary according to the degree of hypoxia. Thus, a gene product which has therapeutic activity can be targetted to cells affected by disease, eg. tumour cells.

[0008] The species encoded by the gene in the construct according to the invention may be for example a cytokine, such as Interleukin-2 (IL-2) which is known to be active in the immune response against tumours. Genes encoding other molecules which have an antitumour effect may also be used.

[0009] In a preferred embodiment of the construct according to the invention, the species encoded by the gene is a pro-drug activation system, for example the thymidine phosphorylase enzyme, which converts a relatively inactive drug into a much more potent one. Transfection of the thymidine phosphorylase gene into human breast cancer cells has been shown to greatly increase the sensitivity of the cancer cells to 5-deoxy-5FU (see Example 8). The thymidine phosphorylase gene has not previously been reported as an agent for gene therapy. Another pro-drug activation system which can be used is cytosine deaminase, which activates the pro-drug 5-fluorocytosine (5-FC) to form the antitumour agent 5-fluorouracil (5-FU). A further example of a pro-drug activation system for use in the invention is cytochrome p450 to activate the drug SR4233 (Walton et al, 1992).

[0010] The construct according to the invention may contain more than one gene and more than one type of gene. Additional genes may encode further species having activity against disease, or they may have gene products with other activities.

[0011] Hypoxically-inducible promoters or enhancers may be chosen from those referred to herein, or they may be other hypoxically-inducible promoters or enhancers. It is anticipated that other hypoxically-inducible promoters or enhancers will be discovered; oxygen-sensing systems are widespread in mammalian cells and many genes are likely to be under hypoxic control.

[0012] Preferably, the nucleic acid construct according to the invention comprises at least one hypoxia response element which confers hypoxia inducibility on the expression control sequence. There may be for example two or more

hypoxia response elements linked so as to increase hypoxia inducibility and thus to increase the induction of the gene or genes under hypoxia. Hypoxia response elements may be chosen from among those referred to herein, or they may be other hypoxia response elements. As noted above, oxygen-sensing systems are widespread in mammalian cells, and it is expected that other hypoxia response elements will be found.

[0013] The following hypoxia response elements may be used in the construct according to the invention:-

a) The following portion of the transcriptional enhancer lying 3' to the mouse erythropoietin (Epo) gene:

GGG CCC TAC GTG CTG CCT CGC ATG G (25) [SEQ ID NO: 1]

b) One of the following portions of the 5' flanking sequence of the mouse phosphoglycerate kinase (PGK) gene:

CGC GTC GTG CAG GAC GTG ACA AAT (P24) [SEQ ID NO: 2] or
GTC GTG CAG GAC GTG ACA (P18) [SEQ ID NO: 3]

[0014] These PGK sequences have not been previously recognised as having hypoxically-inducible properties.

[0015] All of these sequences have counterparts in human genes and are highly conserved between species. They are also well characterised.

[0016] The invention therefore also provides a hypoxically inducible expression control sequence which comprises the nucleic acid sequence:

CGC GTC GTG CAG GAC GTG ACA AAT (P24) [SEQ ID NO: 2] or
GTC GTG CAG GAC GTG ACA (P18) [SEQ ID NO: 3]

or a nucleic acid sequence with substantial homology thereto. These sequences can be found in EMBL database, accession no. M18735, at nucleotides 631 to 654 and 634 to 651.

[0017] The construct according to the invention may comprise more than one eg. three or more copies of one of the Epo or PGK sequences given above. Additionally or alternatively, a longer portion of the Epo or PGK-1 enhancer or flanking sequence may be used in the construct, which longer portion comprises the hypoxia response element and part of the surrounding sequence.

[0018] Hypoxically-inducible expression control sequences and hypoxia response elements may be chosen so as to be operative in particular tissues or cell types to be targetted therapeutically, or they may be chosen to work in a wide range of tissues or cell types.

[0019] The invention further provides a nucleic acid construct as described herein for use in the treatment of a patient suffering from a disease in which hypoxia is a cause or a symptom or is otherwise present. Alternatively, the invention provides the use of a nucleic acid construct as described herein in the preparation of a composition for the treatment of a patient suffering from a disease in which hypoxia is a cause or a symptom or is otherwise present, which method comprises administering to the patient a nucleic acid construct as described herein.

[0020] The nucleic acid constructs will be useful for treating cancer patients. In hypoxic tumour cells, the physiological stimuli will be such that the gene which has activity against the disease is expressed. Although it may be very difficult to get all cells to take up the gene to switch it on, experiments show that even with 10% of cells expressing the thymidine phosphorylase gene there is an effect on other cells which results in a 10-fold increase in sensitivity of the whole population. This is known as the bystander effect and is probably due to active metabolites of the anticancer drug passing from one cell to another.

Since this drug kills proliferating cells, it should still have much less toxicity on normal tissue than on cancer cells. Sometimes, nearby normal cells will also express the gene and the active drug or cytokine or other species encoded by the gene will be able to diffuse from the normal cells into the tumour.

[0021] The inventors have demonstrated both stable and transient transfection of cells with genes under the control of hypoxically inducible enhancers. Transient transfection only lasts for a few days, whereas stably transfected genes insert into the cell genome and can persist indefinitely. Stable transfection may prove to be necessary for therapeutic

applications of the invention but it is possible that transient transfection will be sufficient.

[0022] Administration of constructs according to the invention for therapeutic purposes can be by injection of DNA directly into the solid tumour. Certain types of cell including tumour cells, skin cells and muscle cells take up naked DNA, and tumour cells do so particularly well. The constructs may thus be administered in the form of naked DNA plasmids. Alternatively other vectors such as retroviruses may be used.

[0023] A suitable therapeutic regime will be direct injection of DNA into the affected site, and administration of pro-drug in the case of a construct encoding a pro-drug activation system, optionally combined with radiotherapy.

[0024] Although the invention is described above in relation to targeting of tumour cells, it will also be useful in other types of disease where hypoxia occurs, including for example coronary artery disease and strokes. The nucleic acid construct may comprise a gene encoding a pro-drug activation system for a suitable drug or the gene may encode a cytokine or a growth factor. A vascular growth factor can be used to stimulate new blood vessel formation in hypoxic areas and expression of the growth factor by the construct will then be automatically switched off when the area becomes revascularised.

[0025] The inventors have carried out deletional analysis and mutational analysis of the mouse Epo enhancer sequence, in the cell lines HepG2 and a23 (a23 are non-Epo producing cells). Transient transfection experiments were performed using plasmids containing full or partial enhancer sequences lying 1.4 kb 5' to the α_1 globin reporter gene.

[0026] Three critical sites for enhancement were defined, corresponding to the nucleotides 5 - 12, 21 - 24 and 33 - 34 of the 96 nucleotide enhancer sequence (mouse Epo enhancer: EMBL accession no. X73471). All three regions were absolutely necessary for enhancer function in the above experiments. But overall, studies indicated that the 1-25 or 1-26 nucleotide sequence has hypoxically inducible operation (EMBL, X73471, nucleotides 407 to 431 or 432). Inducible operation via the 1 - 26 nucleotide sequence was also demonstrated for MEL and HeLa cells, which have previously been found unable to support oxygen-regulated reporter gene expression using plasmids containing the 1 - 96 nucleotide enhancer sequence (Maxwell et al 1993). A total of 19 cell lines (some unreported) have now been tested by the inventors and none has been found to lack the capacity to modulate oxygen dependent changes in reporter gene expression by the sequence 1 - 26. Thus, whereas it was previously suggested that the hypoxically inducible response was not universal in mammalian cells, it now seems more likely that it is.

[0027] Recent studies of the human Epo enhancer also define at least three critical regions of the sequence (Semenza et al 1992 and Blanchard et al 1992).

[0028] The examples which follow contain experimental demonstrations by the inventors which indicate the manner in which different aspects of the invention work.

EXAMPLES

Example 1

Action of Subsequences from the Mouse Epo Enhancer on an Adjacent SV40 Promoter

[0029] Figure 1 (A) shows the structure of the test plasmids, where E represents Epo enhancer sequence, SV40P represents the SV40 early promoter and GH represents the body of the growth hormone gene. The Epo enhancer sequence (E) used in each test plasmid is indicated beneath the corresponding bars of the histogram. A co-transfected plasmid containing the α_1 globin gene alone (pBS α) was used to correct for transfection efficiency. Expression is normalised to that of the enhancerless pSVGH in normoxic cells and represents the mean \pm S.D. of three independent experiments (B). Inducible activity is conveyed by sequence 1 - 25 in all cell types. Inducible activity was much increased by concatamerization of this sequence which also conveyed some constitutive activity in normoxic cells (1 - 25)₂ and (1 - 25)₃. In contrast, neither constitutive nor inducible activity was conveyed by sequence 25 - 60 in any cell type. Concatamers of this sequence were tested in either orientation (25 - 60)₃ and (60 - 25)₄ but none had any action. The monomeric sequence 1 - 60 was more active than the monomeric sequence 1 - 25 in HepG2 cells and a23 but not MEL cells.

Example 2

Oxygen-Regulated Control Elements in the PGK-1 and LDH-A Genes

[0030] The materials and methods below are employed in Examples 3 - 6.

Cell lines and culture conditions

[0031] The cell lines used were HepG2 (human hepatoma), HeLa (human cervical carcinoma) and L cells (mouse

fibroblast) grown in minimal essential medium, with Earle's salts, supplemented with fetal bovine serum (10%), glutamine (2mM), penicillin (50 units/ml) and streptomycin sulfate (50µg/ml). For assay of endogenous gene expression, and for preparation of nuclear extracts, cells were grown to approximately 70% confluence. The medium was then replaced, and cells subjected to the following conditions for 14 - 16 hours: (1) normoxia (20% oxygen, with 5% CO₂ and 75%N₂); (2) hypoxia (1% oxygen, with 5% CO₂ and 94% N₂ in Napco 7100 incubator); (3) hypoxia with cycloheximide (100 µM); (4) normoxia with cobaltous chloride (50 µM); (5) normoxia with cyanide (100µM); (6) hypoxia with cyanide (100µM).

Transient Transfection

[0032] In all experiments the test plasmid (10-100 µg), containing either human α_1 globin (α) or human growth hormone (GH) as a reporter, was cotransfected with a control plasmid (10 - 50 µg) using electroporation as previously described (Pugh et al. 1991). The control plasmid, whose expression was not altered by hypoxia, was either the human α_1 globin gene, when the test plasmid contained GH; or FGH, a fusion gene consisting of the mouse ferritin promoter (290 bp) linked to the human growth hormone gene, when the test plasmid contained the α globin gene.

[0033] Details of test plasmid design are as follows. The mouse PGK-1 5' flanking sequence used in the basic construct (pPGKGH) was a 502 bp fragment of the PGK-1 sequence in pDEneo, extending from the EcoR1 site at -523 bp (1 = translational initiation) to the TaqI site at -21 bp. The mouse LDH-A gene sequence in pLDHGH was generated by PCR amplification from mouse genomic DNA of a 233 bp fragment (-186 to +47 from transcriptional start site) using oligonucleotides derived from published sequence. Plasmid DNA for transfection was purified on a caesium gradient; nucleotide sequence of the crucial elements of all plasmids was confirmed by direct sequencing.

[0034] After electroporation transfected cells were split equally and incubated in parallel for 14 - 16 hours in 8 ml of culture medium in 100 mm Petri dishes under normoxic or hypoxic conditions, or exposed to chemical agents, as described above.

RNA analysis

[0035] RNA was extracted, analysed by RNase protection, and quantitated as previously described (Pugh et al 1991). For assay of transiently transfected material 3-10 µg of RNA was subjected to double hybridisation with probes which protected 120 bp of GH mRNA and either 132 bp (α 132) or 97 bp (α 97) of α globin mRNA, depending on whether the test or control plasmid contained α globin.

[0036] For assay of endogenous PGK-1 gene expression 50 µg of RNA extracted from HepG2 cells was hybridised with a riboprobe which consisted of 121 bp from the 5' end of the exon 3 of the human PGK-1 gene, together with 68 bp of adjacent intron (obtained by PCR of genomic DNA and cloning by standard methods). For assay of endogenous LDH-A gene expression 25 µg of RNA obtained from L cells was hybridised with a riboprobe which consisted of 47 bp from the 5' end of exon 1 of the mouse LDH-A gene, together with adjacent 5' flanking sequence (obtained by PCR of genomic DNA and cloning by standard methods). In these experiments a small quantity (0.5 µg) of RNA extracted from K562 cells (a human Epo cell line which expresses α globin mRNA abundantly) was added to each sample before hybridisation, and the samples were probed concurrently with the α 97 probe in addition to the PGK-1 or LDH-A probe. This provided a means of determining that sample processing and gel loading was comparable between specimens.

Nuclear Extract

[0037] Cells were cooled rapidly, harvested into ice cold phosphate buffered saline, and pelleted at 2000 g. A modification of Dignam's protocol was used to prepare nuclear extract. Briefly, cells were swollen for 10 minutes in Buffer A (10mM Tris-HCl pH 7.4, 10mM KCl, 1.5 mM MgCl₂), lysed using a Dounce homogenizer, and extracted for 30 minutes in Buffer C (20 mM Tris-HCl, pH 7.4, 420 mM KCl, 1.5 mM MgCl₂, 20% glycerol). Nuclear debris was pelleted at 10000 g and the supernatant dialysed for 2 hours against Buffer D (20 mM Tris-HCl pH 7.4, 100 mM KCl, 0.2 mM EDTA, 20% glycerol). The entire procedure was performed at 4°C using precooled buffers. In addition buffers A and C contained phenylmethylsulfonyl fluoride, 0.5 mM; aprotinin, 1 µg/ml; leupeptin, 1 µg/ml; pepstatin, 1 µg/ml; sodium orthovanadate, 1mM; benzamidin, 0.5 mM; levamisole, 2 mM; β glycerophosphate, 10 mM; DTT, 0.5 mM. Sodium orthovanadate and DTT were also added to buffer D. Following dialysis, aliquots of nuclear extract were frozen in a dry ice/ethanol bath and stored at -70°C.

Electrophoretic Mobility Shift Assays

[0038] Oligonucleotides used as probes or competitors were purified by polyacrylamide gel electrophoresis. Labelling was performed with {gamma- ³²P}ATP (3000Ci/mmol) using T₄ polynucleotide kinase. Labelled oligonucleotides were

annealed with 4 x molar excess of the complementary strand. Unlabelled oligonucleotides were annealed in molar equivalent quantities.

[0039] The binding reactions were performed in a 20 µl volume containing 50 mM KCl, 1 mM MgCl₂, 0.5 mM EDTA, 5 mM DTT, 5% glycerol, and 0.15-0.30 µg of sonicated polydIdC. Nuclear extract (5 µg unless otherwise stated) was incubated with this mixture for 5 minutes at room temperature, before probe (approximately 0.5 ng) and specific competitors were added. Incubation was continued for a further 10 minutes. Reactions were electrophoresed (12.5 v/cm) at 4°C using 5% polyacrylamide in 0.3 x TBE (pH 7.3 at 4°C).

Example 3

RNA Analysis of PGK-1 and LDH-A Gene Expression

[0040] Expression of the endogenous human PGK-1 gene in HepG2 cells and of the endogenous mouse LDH-A gene in L cells was assayed by RNA analysis. Cells were exposed for 16 hours to normoxia (20% O₂) hypoxia (1% O₂) and cycloheximide 100 µM, normoxia and cobaltous chloride 50 µM, normoxia and cyanide 100 µM, hypoxia and cyanide 100 µM. 50 mg RNA was used for each hybridisation reaction. For each gene, both hypoxia and exposure to cobalt led to a 2 - 3 fold induction of gene expression. The protein synthesis inhibitor cycloheximide abrogated the response to hypoxia. Cyanide did not affect the hypoxic response, neither inducing expression in normoxia, nor preventing induction by hypoxia.

Example 4

Location of Sequences Responsible for Hypoxia Inducible Expression of the Endogenous PGK-1 and LDH-A Genes

[0041] Portions of the 5' flanking sequence of PGK-1 and LDH-A genes were linked to a growth hormone receptor gene. Expression in transfected HepG2 cells of fusion genes containing either a 502 bp fragment from the PGK-1 enhancer/promoter region (pPGKGH) or a 233 bp sequence from the LDH-A promoter (pLDHGH), was measured after exposure to conditions of hypoxia, normoxia etc. as used in Example 3. In each case hypoxically inducible expression was conveyed by the sequences, a somewhat greater level of inducibility being observed than for the respective endogenous gene. The inducible operation of these sequences contrasted with the SV40 virus promoter, the α globin promoter, the ferritin promoter and the herpes simplex thymidine kinase promoter, none of which had this property. Responses were not specific for HepG2 cells and similar inducible responses were obtained in transfected HeLa cells.

[0042] In this example, 5 µg of RNA was used for each hybridisation reaction, and the α132 and GH probes were used to detect expression of the transfection control and test plasmids respectively.

Example 5

Deletional Analysis of the PGK-1 Enhancer Region

[0043] Figure 2 shows (A) partial nucleotide sequence of the 253 bp EcoR1 - Spe1 fragment containing the enhancers (EMBL accession no. M18735, nucleotides 417 to 676). The positions of deletions (D) from the 5' end of the sequence are marked by arrows. Figure 2 (B) shows the ratio of hypoxic to normoxic expression conferred on the reporter by EcoR1 - Spe1 fragment and deletion thereof. Values represent means of three separate transfections, with bars showing SEM.

[0044] A series of nested deletions was carried out as indicated in figure 2. The greatest reduction in the amplitude of hypoxic induction occurred with deletion of 20 bp between D9 and D11. The functional importance of this region was confirmed by the finding that a pGKGH fusion gene from which 18 bp between the positions of D9 and D11 had been removed no longer demonstrated hypoxic inducibility.

Example 6

Functional Analysis of the Oxygen Regulated Element of the PGK Enhancer

[0045] For analysis of the functional characteristics of this isolated sequence (the 18 bp sequence described in Example 5), oligonucleotides were cloned into a site 10 bp 5' to the TATA box of the herpes simplex thymidine kinase promoter in a thymidine kinase - growth hormone fusion gene. The 18 bp element (P18) whose deletion abrogated hypoxic induction of the PGKGH construct, was capable of conferring responsiveness to hypoxia when placed in either orientation. Concatamers operated more powerfully than monomers. Extension of P18 to a 24 bp element (P24) did

not lead to increased activity.

Example 7

5 Stable Transfection of Cells with the PGK-1 Hypoxic Promoter

[0046] HeLa cells were transfected by electroporation with supercoiled plasmid DNA. Stably transfected cells were selected by growth in G418 medium. Two plasmids were transfected. The first contained a hypoxic promoter coupled to the gene for the cell surface marker CD2 and the second contained the same hypoxic promoter coupled to the gene for the enzyme cytosine deaminase as well as a constitutively acting promoter (SV40 early region promoter) coupled to a neomycin resistance region. The hypoxic promoter used in this transfection experiment consisted of a 456 bp Sph-1/Taq-1 fragment from the mouse PGK-1 5' flanking sequence into which 3 copies of the active sequence P24 had been inserted at the Spe-1 site.

[0047] This system was designed in order to enable us to create signal pathway mutant cells. Essentially the CD2 and cytosine deaminase genes are being used as selectable markers and the neomycin resistance gene provides a means of retaining the transfected plasmid and therefore selecting cells which have lost the response rather than the transfected genes. It is clear that the principle of selectable markers can be used to kill unwanted cells, according to the invention.

[0048] After transfection cells were grown for two weeks and pools were subject to a 16 hour incubation at either 21% oxygen (normoxia) or 1% oxygen (hypoxia). Marker gene expression was quantified by RNA analysis. Approximately 10 fold increased expression was observed at 1% oxygen versus 21%. Thus, the selectable marker genes were under the control of the hypoxically inducible promoter.

Example 8

25 Transfection of Human Breast Cancer Cell Line with Thymidine Phosphorylase Gene

[0049] Human breast cancer cells of the cell line MCF-7 were transfected with a gene for thymidine phosphorylase. Thymidine phosphorylase can convert a relatively inactive drug into a much more potent product. The gene is suitable for linking up with hypoxically-inducible promoters/enhancers.

[0050] As a general principle, when genes are transfected into cancer cells they will be expressed at different levels and so it is important to study several different clones of the cells to see the variability.

[0051] Results of drug sensitivity experiments are shown in Figures 3 - 7. -7, -4, -12, +4 and +16 are all derivatives of MCF-7 which have been transfected with the thymidine phosphorylase gene.

[0052] Figure 3 shows a survival curve for the parent cell line MCF-7 in breast cancer (WT) and a derivative from it that has been transfected with a gene for thymidine phosphorylase. There is relatively little difference in their sensitivity to the drug 5FU. However, the transfectant (-4) is nearly 200 fold more sensitive to 5-deoxy 5FUdR (Figure 4).

[0053] Figure 5 shows clones -12 and -4 are particularly sensitive to the drug 5-deoxy 5FUdR compared to the wild-type. Two other transfectants -7 and +4 and -16 are a little bit more sensitive than the wild-type. Note that there is a log scale and therefore the IC50 (the concentration of drug required to inhibit growth by 50%) is more than 100 times lower for the transfectants -12 and -4. Therefore, the expression of one gene at a higher level can make these cells 100 times more sensitive to chemotherapy.

Clearly there is variation depending on the level of expression and therefore we want to be able to switch on as high as possible. The pro-drug 5-deoxy 5FUdR is broken down to 5FU and a comparison of the sensitivity of the cells to 5FU in figure 6 reveals that there is really very little difference. This means that it is the activation step that is important rather than downstream events.

[0054] Finally, when a drug has been activated by the cancer cells it could be transferred to other cells which would normally be resistant but the active form of the drug can overcome this. To demonstrate, the sensitive cells (-4 cells) and the wild-type cells were mixed together, and it can be seen from figure 7 that the IC50 drops from 11.6 μ M to 1.5 μ M i.e. one log 10-fold increase in sensitivity with only 20% of the cells expressing the drug activation gene. Thus, in gene therapy it will not be necessary to get all of the cells to express the gene, only perhaps 20%.

[0055] This demonstrates that the target gene thymidine phosphorylase is useful as a mechanism of activating an anticancer drug and that overexpressing it in even a proportion of cells can confer drug sensitivity, not only these cells but adjacent cells.

Example 9

Stable Transfection of Cells with PGK-1 Hypoxically Inducible Elements and Different Promoters

[0056] The PGK-1 hypoxia response element was evaluated within the context of the PGK-1 gene promoter (M3), the 9-27 gene promoter (9-3C) and the thymidine kinase gene promoter (sTK5).

[0057] The constructs were similar to those described in Example 7. The promoters and PGK-1 hypoxia response elements were placed upstream of genes encoding the endothelial CD2 surface protein and the negative selectable marker cytosine deaminase. The 9-27 and thymidine kinase promoters were each used with 3 copies of the P18 PGK-1 element and the PGK-1 gene promoter was used with 3 copies of the P24 PGK-1 element.

[0058] The stable transfectants were tested for their response to severe hypoxia (0.001% and 0% O₂) and different levels of oxygen (0.1, 1, 2, 5 and 20% O₂). Cell-surface expression of transfected CD2 was analysed using fluorescence-labelled anti-CD2 antibodies. Labelled cells were assayed for CD2 expression on a fluorescence activated cell sorter.

[0059] The increase in CD2 production depended on the length and severity of hypoxia. Following severe hypoxia, CD2 expression in the transfected lines only increased following subsequent aeration (maximal at 5 hours post hypoxia), whereas, following less severe hypoxia conditions, CD2 expression peaked immediately after hypoxia.

[0060] 1% O₂ induced CD2 expression, but not to the same degree as severe hypoxia (<5ppm). 5% and 20% O₂ did not result in any CD2 induction.

[0061] CD2 expression persisted for 24 hours following reoxygenation.

[0062] Figures 8a, b and c show CD2 induction data for M3, sTK5 and 9-3C respectively, with oxygen at 5%, 2%, 1%, 0.001% (N₂, almost no oxygen), 0%O₂ (AnO₂). n represents the number of experiments performed. CD2 expression was measured immediately following treatment (0h) and five hours post-treatment (5h).

Example 10

Hypoxia-Induced Pro-Drug Sensitisation

[0063] The bacterial enzyme cytosine deaminase catalyses the conversion of cytosine to uracil, and can therefore change the pro-drug 5-fluorocytosine (5-FC) to the antitumour agent 5-fluorouracil (5-FU).

[0064] Transfected cells (9-3C and M3) as described in Example 9 were tested for sensitivity to 5-FC. Cells were subjected to hypoxic exposure (16 hours), followed by exposure to 5-FC or 5-FU (24 hours), followed by a 96 hour growth delay.

[0065] Results are shown in figures 9a and b (Wt represents non-transfected HT1080 cells). M3 and 9-3C cell lines were significantly more sensitive to 5-FC post-hypoxia (Fig 9a). There was no significant difference in 5-FU sensitivity in control (Wt) or transfectant cells following hypoxic or normoxic treatment (Fig 9b).

Example 11

In vivo Experiment in Mice

[0066] Tumour cells (HT1080 cells) were transfected with a DNA construct containing the CD2 gene linked to a promoter containing the PGK-1 hypoxia response element (as described in Example 9). About a million transfected cells were implanted under the skin of a mouse. The tumour was later excised and histologically sectioned. Staining with anti-CD2 antibodies indicated hypoxically-induced expression of the marker gene.

References

- [0067] Blanchard, K.L., Acquaviva, A.M., Galson, D.L. and Bunn, H.F. (1992) Mol. Cell. Biol. 12, 5373-5385.
- [0068] Maxwell P.H., Pugh C.W. and Ratcliffe P.J. (1993), Proc. Natl. Acad. Sci. USA, vol. 90, p.2423-2427.
- [0069] McBurney M.W., Sutherland L.C., Adra C.N., Leclair B. et al (1991), Nucleic Acids Research, vol 19, no. 20, p. 5755-5761.
- [0070] Pugh C.W., Tam C.C., Jones R.W. and Ratcliffe P.J. (1991), Proc. Natl. Acad. Sci. USA, vol. 88, p. 10553-10557.
- [0071] Pugh C.W., Ebert B.L., Ebrahim O. and Ratcliffe P.J. (in press), Biochimica et Biophysica Acta.
- [0072] Semenza G.L., Nejfelt M.K., Chi S.M. and Antonarakis S.E. (1991), Proc. Natl. Acad. Sci. USA, vol. 88, p. 5680-5684.
- [0073] Semenza, G.L. & Wang, G.L. (1992) Mol. Cell. Biol. 12, 5447-5454.

- [0074] Vile R.G. and Hart I.R. (1993), Cancer Research, vol 53, p.962-967.
 [0075] Walton M.I., Wolf C.R., Workman P. (1992), Biochem Pharmacol., vol 44, p. 251-259.
 [0076] Workman P. and Stratford I.J. (1993), Cancer and Metastasis Reviews, vol 12, p.73-82.

5

Claims

10

15

20

25

30

35

1. A nucleic acid construct comprising at least one gene encoding a cytokine or a pro-drug activation system, operatively linked to a hypoxically inducible expression control sequence.
2. A construct as claimed in claim 1, wherein the expression control sequence comprises a promoter or an enhancer.
3. A construct as claimed in claim 1 or claim 2, wherein at least one hypoxia response element confers hypoxia inducibility on the expression control sequence.
4. A construct as claimed in claim 3, comprising 2 or more hypoxia response elements.
5. A construct as claimed in claim 3 or claim 4, wherein the hypoxia response element is the P18 or P24 PGK-1 sequence (SEQ ID NO:3 or SEQ ID NO: 2) or a sequence with substantial homology thereto.
6. A construct as claimed in any one of claims 1 to 5, wherein the prodrug activation system is an enzyme capable of converting a pro-drug to an active drug.
7. A construct as claimed in claim 6, wherein the enzyme is cytosine deaminase.
8. A construct as claimed in any one of claims 1 to 7, in the form of a vector such as a plasmid.
9. A construct as claimed in any one of claims 1 to 8, for use in the treatment of a patient suffering from a disease in which hypoxia is a cause or a symptom or is otherwise present.
10. Use of a nucleic acid construct as claimed in any one of claims 1 to 9 in the preparation of a composition for the treatment of a patient suffering from a disease in which hypoxia is a cause or a symptom or is otherwise present.
11. A hypoxically-inducible expression control sequence which comprises at least one copy of the P18 or P24 PGK-1 sequence (SEQ ID NO:3 or SEQ ID NO: 2) or a sequence with substantial homology thereto, operatively linked to a gene encoding a species having activity against disease.

40

Revendications

45

50

55

1. Produit d'assemblage d'acide nucléique comprenant au moins un gène codant pour une cytokine ou un système d'activation de précurseur médicamenteux, lié de manière fonctionnelle à une séquence de régulation d'expression inductible par hypoxie.
2. Produit d'assemblage suivant la revendication 1, dans lequel la séquence de régulation d'expression comprend un promoteur ou un activateur.
3. Produit d'assemblage suivant la revendication 1, ou la revendication 2, dans lequel au moins un élément de réponse à l'hypoxie confère une inductibilité par hypoxie à la séquence de régulation d'expression.
4. Produit d'assemblage suivant la revendication 3, comprenant 2 ou plus de 2 éléments de réponse à l'hypoxie.
5. Produit d'assemblage suivant la revendication 3 ou la revendication 4, dans lequel l'élément de réponse à l'hypoxie est la séquence de PGK-1 P18 ou P24 (SEQ ID n° 3 ou SEQ ID n° 2) ou une séquence présentant une homologie substantielle avec celle-ci.
6. Produit d'assemblage suivant l'une quelconque des revendications 1 à 5, dans lequel le système d'activation de précurseur médicamenteux est une enzyme capable de convertir un précurseur médicamenteux en un médicament

actif.

7. Produit d'assemblage suivant la revendication 6, dans lequel l'enzyme est la cytosine-désaminase.
8. Produit d'assemblage suivant l'une quelconque des revendications 1 à 7, sous forme d'un vecteur tel qu'un plasmide.
9. Produit d'assemblage suivant l'une quelconque des revendications 1 à 8, destiné à être utilisé dans le traitement d'un patient souffrant d'une maladie dans laquelle l'hypoxie est une cause ou un symptôme, ou bien existe par ailleurs.
10. Utilisation d'un produit d'assemblage d'acide nucléique suivant l'une quelconque des revendications 1 à 9 dans la préparation d'une composition pour le traitement d'un patient souffrant d'une maladie dans laquelle l'hypoxie est une cause ou un symptôme, ou bien est par ailleurs présente.
11. Séquence de régulation d'expression inductible par hypoxie, qui comprend au moins une copie de la séquence de PGK-1 P18 ou P24 (SEQ ID n° 3 ou SEQ ID n° 2) ou une séquence présentant une homologie substantielle avec celle-ci, liée de manière fonctionnelle à un gène codant pour une entité douée d'activité contre une maladie.

Patentansprüche

1. Nukleinsäurekonstrukt mit wenigstens einem Gen, welches ein Cytokin oder ein Prowirkstoff-Aktivierungssystem, welches wirksam mit einer hypoxisch induzierbaren Expressionskontrollsequenz verbunden ist, codiert.
2. Konstrukt nach Anspruch 1, worin die Expressionskontrollsequenz einen Promotor oder einen Verstärker enthält.
3. Konstrukt nach Anspruch 1 oder Anspruch 2, worin wenigstens ein Hypoxie-Antwortelement der Expressionskontrollsequenz Hypoxie-Induzierbarkeit verleiht.
4. Konstrukt nach Anspruch 3, welches 2 oder mehr Hypoxie-Antwortelemente enthält.
5. Konstrukt nach Anspruch 3 oder Anspruch 4, worin das Hypoxie-Antwortelement die P18 oder P24 PGK-1-Sequenz (SEQ ID NO:3 oder SEQ ID NO:2) oder eine Sequenz mit erheblicher Homologie dazu ist.
6. Konstrukt nach einem der Ansprüche 1 bis 5, wobei das Pro-Wirkstoff-Aktivierungssystem ein Enzym ist, welches in der Lage ist, einen Pro-Wirkstoff in einen aktiven Wirkstoff zu überführen.
7. Konstrukt nach Anspruch 6, wobei das Enzym Cytosindesaminase ist.
8. Konstrukt nach einem der Ansprüche 1 bis 7 in der Form eines Vektors, wie einem Plasmid.
9. Konstrukt nach einem der Ansprüche 1 bis 8 für die Verwendung bei der Behandlung eines Patienten, der an einer Krankheit leidet, bei der Hypoxie eine Ursache oder ein Symptom oder in anderer Weise vorhanden ist.
10. Verwendung eines Nukleinsäurekonstrukts nach einem der Ansprüche 1 bis 9 zur Herstellung einer Zusammensetzung für die Behandlung eines Patienten, der an einer Krankheit leidet, bei der Hypoxie eine Ursache oder ein Symptom oder in anderer Weise vorhanden ist.
11. Hypoxisch induzierbare Expressionskontrollsequenz, welche wenigstens eine Kopie der P18 oder P24 PGK-1-Sequenz (SEQ ID NO:3 oder SEQ ID NO:2) oder eine Sequenz mit erheblicher Homologie dazu enthält und welche wirksam mit einem Gen verbunden ist, das eine Spezies mit Aktivität gegen Krankheit codiert.

Fig.1.




Fig.2.





Fig.3.




Fig.4.




Fig.5.




Fig.6.




Fig.7.




Fig.8a




Fig.8b




Fig.8c




Fig.9a





Fig.9b



2. HYPOXIA - REGULATED TRANSGENE EXPRESSION IN EXPERIMENTAL RETINAL AND CHOROIDAL NEOVASCULARISATION.

BIO 06-47 06-512821 NDN- 244-0256-2153-0

Mistry, A.; Bainbridge, J.; Ali, R. R.; de Alwis, M.; Binley, K.; Naylor, S.

JOURNAL NAME- ARVO Annual Meeting Abstract Search and Program Planner

VOL. 2003

2003

PP. Abstract No. 1081.

DOCUMENT TYPE- Meeting

ADDRESS- Dept of Molecular Genetics, Institute of Ophthalmology, London, UK, UK

SPONSOR- Association for Research in Vision and Ophthalmology

CONFERENCE DATE- May 04-08, 2003

CONFERENCE TITLE- Annual Meeting of the Association for Research in Vision and Ophthalmology

LANGUAGE- ENGLISH

Purpose: Neovascularisation of the retina and choroid is a central feature of diabetic retinopathy and age-related macular degeneration respectively. These conditions are leading causes of blindness in developed countries for which current treatments are of limited efficacy and associated with significant adverse effects. **Gene therapy** strategies, using recombinant viral vectors, to achieve local, sustained delivery of angiostatic proteins offers a powerful novel approach for the treatment of these disorders. The application of such strategies, however, may also require regulated gene expression to minimise the potential for unwanted adverse effects. In this study we have evaluated the potential of an optimised hypoxia-responsive promoter (OBHRE) to control gene expression. Methods: Hypoxia activates a signalling cascade that culminates in the stabilisation of the HIF-1 transcription factor and activation of genes such as VEGF and **erythropoietin** that possess a hypoxia response element (HRE). We have developed an optimised synthetic hypoxia responsive promoter (OBHRE) that is highly activated by hypoxia but has a low basal activity in normoxia (Binley et al., **Gene Therapy** 1999, Binley et al, Blood 2002). AAV vectors carrying a GFP reporter gene driven by the OBHRE promoter (rAAV.HRE.GFP) were evaluated in a well-characterised murine model of ischaemia-induced VEGF-dependent retinal neovascularisation as well as in a murine model of laser-induced choroidal neovascularisation. Results: In murine ischaemia-induced retinal neovascularisation, intravitreal delivery of rAAV.HRE.GFP results in reporter gene expression specifically at sites of vascular closure during the period of active neovascularisation, and not after vector delivery in normal controls. In murine laser-induced choroidal neovascularisation, subretinal delivery of rAAV.HRE.GFP results in reporter gene expression at sites of active neovascularisation but not elsewhere or after vector delivery in normal controls. Conclusions: OBHRE-driven gene expression offers an attractive strategy for the targeted and regulated delivery of angiostatic proteins to the retina in the management of neovascular disorders.